Vicarious Surgical Is Maintained at Neutral by Piper Sandler
Vicarious Surgical Analyst Ratings
Promising Milestones and Financial Prudence Drive Buy Rating for Vicarious Surgical
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Raises Target Price to $13
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
Morgan Stanley Maintains Vicarious Surgical(RBOT.US) With Hold Rating, Cuts Target Price to $6.5
Vicarious Surgical Analyst Ratings
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Maintains Target Price $10
Piper Sandler Maintains Vicarious Surgical(RBOT.US) With Hold Rating, Cuts Target Price to $12
Piper Sandler Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
Vicarious Surgical's Progress and Upcoming Milestones Merit a Buy Rating
Vicarious Surgical Analyst Ratings
Morgan Stanley Cuts Price Target on Vicarious Surgical to $10 From $18, Keeps Equalweight Rating
Vicarious Surgical (RBOT) Gets a Hold From Piper Sandler
Buy Rating Affirmed: Vicarious Surgical's Advancements Poised to Disrupt Medical Robotics
A New Cause for Concern: Vicarious Surgical Inc. Adds a New Share Price & Shareholder Rights Risk
Vicarious Surgical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Vicarious Surgical (RBOT) and 89bio (ETNB)
BTIG Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
BTIG Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
No Data
No Data